Submitted by Automa??o e Estat?stica (sst@bczm.ufrn.br) on 2017-04-04T18:40:22Z
No. of bitstreams: 1
CamillaCarlaDoNascimentoDantasCardoso_DISSERT.pdf: 1584071 bytes, checksum: f40f4e02e45ed4aae3bbf022f745a170 (MD5) / Approved for entry into archive by Arlan Eloi Leite Silva (eloihistoriador@yahoo.com.br) on 2017-04-12T21:48:51Z (GMT) No. of bitstreams: 1
CamillaCarlaDoNascimentoDantasCardoso_DISSERT.pdf: 1584071 bytes, checksum: f40f4e02e45ed4aae3bbf022f745a170 (MD5) / Made available in DSpace on 2017-04-12T21:48:51Z (GMT). No. of bitstreams: 1
CamillaCarlaDoNascimentoDantasCardoso_DISSERT.pdf: 1584071 bytes, checksum: f40f4e02e45ed4aae3bbf022f745a170 (MD5)
Previous issue date: 2016-12-12 / A doen?a inflamat?ria intestinal (DII) engloba um espectro de dist?rbios inflamat?rios cr?nicos e ? classificada em dois subtipos principais: Colite Ulcerativa (UC) e Doen?a de Chron (DC). O tratamento da UC baseia-se no uso de anti-inflamat?rios, mas estes medicamentos na sua forma convencional geram in?meros efeitos adversos, o que estimula o desenvolvimento de pesquisas focadas na busca por novas terapias e tecnologias aplicadas aos f?rmacos. O objetivo deste trabalho foi avaliar a atividade de micropart?culas revestidas por Biopol?meros de quitosana e goma guar contendo como princ?pio ativo a triancinolona, no intuito de observar a resposta anti-inflamat?ria nos par?metros macro e microsc?picos da mucosa intestinal. Foram utilizados 56 ratos Wistar, divididos em 08 grupos de 7 animais, sendo G1: Controle negativo (aus?ncia de colite), G2: Colite, G3: Sulfassalazina (SSZ 500mg/Kg/dia), G4: Triancinolona (TR) livre 5mg/Kg/dia, G5: TR livre 10mg/Kg/dia, G6: TR livre 15mg/Kg/dia, G7: Micropart?cula de TR (15mg/Kg/dia f?rmaco encapsulado) e o grupo G8: Biopol?meros. Os resultados obtidos quanto ao par?metro de avalia??o macrosc?pica mostraram que o menor grau de les?o, com exce??o do grupo Controle negativo, foi encontrado no grupo dos Biopol?meros e SSZ quando comparado aos demais grupos: Colite, TR 5mg, TR 10mg, TR 15mg e Micropart?cula TR. Na an?lise estat?stica desse par?metro os grupos SSZ 500mg/Kg/dia, TR 15mg/kg/dia, Micropart?cula TR 15mg/Kg/dia e Biopol?meros diferiram estatisticamente quando comparadas ao grupo Colite (p<0,05), sendo esta diferen?a mais significativa no grupo dos Biopol?meros (p<0,01). Na an?lise da perda de peso, o grupo Micropart?cula TR reduziu entre 8 a 12% esse par?metro quando comparado aos grupos da Triancinolona livre, diferindo estatisticamente (p<0,05), evidenciando que a tecnologia empregada foi satisfat?ria quanto a redu??o desse efeito adverso. Na avalia??o histopatol?gica o grupo TR 15mg/kg/dia obteve o menor dano tissular, evidenciando o potencial anti-inflamat?rio do f?rmaco livre. Diante dos resultados sugere-se que a nanotecnologia com o uso das micropart?culas foi capaz de reduzir efeitos adversos, como a perda de peso e, al?m disso, obteve resultados com potencial efeito anti-inflamat?rio, apesar da libera??o de apenas 69% dos 15mg da triancinolona encapsulada em 24 horas. Assim, os estudos voltados para aplica??o da nanotecnologia e novos ativos devem crescer e ampliar com intuito de buscar novas terapias e elucidar mecanismos de a??o ainda n?o descobertos. / The inflammatory bowel disease (IBD) encompasses a spectrum of chronic inflammatory disorders and is classified into two main subtypes: Ulcerative Colitis (UC) and Chron's Disease (CD). The treatment of UC is based on the use of anti-inflammatories, but these drugs in their conventional form generate numerous adverse effects, which stimulates the development of research focused on the search for new therapies and technologies applied to the drugs. The objective of this study was to evaluate the activity of microparticles coated by chitosan and guar gum biopolymers containing as active principle triamcinolone in intention to observe the anti-inflammatory response in the macroscopic and microscopic parameters of the intestinal mucosa. In total, 56 Wistar rats divided into 8 groups in 7 animals, being G1: Negative control (absence of colitis), G2: Colitis, G3: Sulfasalazine (SSZ 500mg/Kg/day), G4: Free triamcinolone (TR) 5mg/Kg/day, G5: Free TR 10mg/Kg/day, G6: Free TR 15mg/Kg/day, G7: Triamcinolone microparticle (15mg/Kg/day), G8: Biopolymers. The results obtained for the macroscopic evaluation showed that the lowest lesion degree, except for the negative control group, was found in the Biopolymer group and SSZ group when compared to the other groups: Colitis, TR 5mg, TR 10mg, TR 15mg and TR microparticle. In the statistical analysis of this parameter, the groups treated with SSZ 500mg/kg/day, TR 15mg/kg/day, TR microparticle 15mg/Kg/day and Biopolymers differed statistically when compared to the Colitis group (p<0.05), this difference being more significant in the Biopolymer group (p<0.01). In the analysis of weight loss, the TR microparticle reduced this parameter between 8 and 12% when compared to the free Triamcinolone groups, differing statistically (p<0.05), suggesting that the technology employed was satisfactory in terms of the reduction of this adverse effect. In the histopathological evaluation, the TR group 15mg/kg/day obtained the lowest tissue damage, evidencing the anti-inflammatory potential of the free drug. In view of the results, it is suggested that nanotechnology with the use of microparticles was able to reduce adverse effects, such as weight loss and, in addition, obtained results with a potential anti-inflammatory effect, despite the release of only 69% of 15mg of encapsulated triamcinolone in 24 hours. Thus, studies aimed at the application of nanotechnology and new assets should grow and expand in order to seek new therapies and elucidate mechanisms of action that have not yet been discovered.
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/22649 |
| Date | 12 December 2016 |
| Creators | Cardoso, Camilla Carla do Nascimento Dantas |
| Contributors | 52904911049, http://lattes.cnpq.br/0021644707162925, Verissimo, Lourena Mafra, 03505558427, http://lattes.cnpq.br/9173400981540256, Vieira, Jeymesson Raphael Cardoso, 02930177438, Camillo, Christina da Silva |
| Publisher | PROGRAMA DE P?S-GRADUA??O EM BIOLOGIA ESTRUTURAL E FUNCIONAL, UFRN, Brasil |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.003 seconds